Back
Oxbridge Re Holdings 10K Form
Buy
71
OXBR
Oxbridge Re Holdings
Last Price:
3.08
Seasonality Move:
16.95%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-09 | 10Q | OXBR/Oxbridge Re Holdings Quarterly |
| 2023-11-14 | 10Q | OXBR/Oxbridge Re Holdings Quarterly |
| 2023-08-14 | 10Q | OXBR/Oxbridge Re Holdings Quarterly |
| 2023-05-12 | 10Q | OXBR/Oxbridge Re Holdings Quarterly |
| 2022-11-14 | 10Q | OXBR/Oxbridge Re Holdings Quarterly |
| 2022-08-15 | 10Q | OXBR/Oxbridge Re Holdings Quarterly |
Receive OXBR News And Ratings
See the #1 stock for the next 7 days that we like better than OXBR
OXBR Financial Statistics
Sales & Book Value
| Annual Sales: | $-7.05M |
|---|---|
| Cash Flow: | $504K |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.59 |
| Price / Book: | 5.25 |
Profitability
| EPS (TTM): | -0.84000 |
|---|---|
| Net Income (TTM): | $-3.99M |
| Gross Margin: | $0 |
| Return on Equity: | -79.13% |
| Return on Assets: | -47.67% |
Oxbridge Re Holdings Earnings Forecast
Key Oxbridge Re Holdings Financial Ratios
- The Gross Profit Margin over the past 3 years for OXBR is 0.00%.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of OXBR is 132.97% of Total Revenues.
- Per Share Earnings over the last 10 years have been positive in 4 years.
Oxbridge Re Holdings Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Insurance |
| Sector: | Financials |
| Current Symbol: | OXBR |
| CUSIP: | G6856M |
| Website: | oxbridgere.com |
Debt
| Debt-to-Equity Ratio: | 0.44 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
OXBR Technical Analysis vs Fundamental Analysis
Buy
71
Oxbridge Re Holdings (OXBR)
is a Buy
Is Oxbridge Re Holdings a Buy or a Sell?
-
Oxbridge Re Holdings stock is rated a Buy
The current Oxbridge Re Holdings [OXBR] share price is $3.08. The Score for OXBR is 71, which is 42% above its historic median score of 50, and infers lower risk than normal.